About Perthera
Perthera is a company based in Mclean (United States) founded in 2012. Perthera has raised $17.02 million across 5 funding rounds from investors including Pilot Growth Equity Partners. The company has 13 employees as of December 31, 2022. Perthera offers products and services including Perthera Report, Virtual Molecular Tumor Board, and RWE Data Pipeline. Perthera operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Tempus, Poseida Therapeutics and Juno Therapeutics, among others.
- Headquarter Mclean, United States
- Employees 13 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Perthera Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$17.02 M (USD)
in 5 rounds
-
Latest Funding Round
$4.47 M (USD), Series A
Sep 30, 2022
- Investors
-
Employee Count
13
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Perthera
Perthera offers a comprehensive portfolio of products and services, including Perthera Report, Virtual Molecular Tumor Board, and RWE Data Pipeline.
Ranks therapy options for cancer patients using AI analysis.
Facilitates physician collaboration for oncology expertise.
Processes real-world evidence for clinical trial matching.
People of Perthera
Unlock access to complete
Unlock access to complete
Funding Insights of Perthera
Perthera has successfully raised a total of $17.02M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $4.47 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Perthera
Perthera has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Pilot Growth Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Growth equity investments are provided to technology entrepreneurs.
|
Locked | Locked | Locked |
Investor details for Perthera
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Perthera
Investment portfolio details for Perthera
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Perthera
Detailed financials for Perthera
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Perthera Comparisons
Peer comparison for Perthera
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Perthera
Perthera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Tempus, Poseida Therapeutics and Juno Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
AI-based precision medicine solutions for oncology are provided.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
Detailed competitors of Perthera
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Perthera
Complete news archive for Perthera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Perthera
Perthera was founded in 2012 and raised its 1st funding round 3 years after it was founded.
Perthera is headquartered in Mclean, United States. It is registered at Mclean, Virginia, United States.
Perthera is a funded company, having raised a total of $17.02M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Perthera is 13.
Perthera was founded in 2012 and is based in McLean, United States, operating in the biotechnology sector focused on oncology. Personalized molecular profiling of tumors is facilitated through genomics and proteomics analyses. The PrecisOn process is employed to integrate these analyses with patient medical history in the Expert Oncologist system (ExpO), a database that incorporates current clinical research and drug information for oncologist guidance.
Perthera's top competitors include Tempus, Juno Therapeutics and Personalis.
Perthera offers Perthera Report, Virtual Molecular Tumor Board, and RWE Data Pipeline.
Perthera has 1 investor. Key investors include Pilot Growth Equity Partners.